Search
Op-EdsConsumers will feel pain if pharmacy benefit managers are over-regulated
Columbus Dispatch: Lowering drug costs should be achieved through marketplace reforms.
Op-Eds340B Drug Discount Program Should Be on GAO’s High-Risk List
RCH: Nothing has been done to reform 340B and stop hospitals and for-profit pharmacies from enriching themselves.
Op-EdsPre-Existing Conditions Will Be Covered by Whoever Wins the Election
Inside Sources: Republicans and President Trump, just like Democrats, believe people with pre-existing conditions should be protected.
Op-EdsLackluster Nursing Home Inspections Added to COVID-19 Deaths
Washington Examiner: Coronavirus has been particularly deadly to residents in nursing homes.
Op-EdsWe Need More COVID-19 Therapies, Not Price Controls
Inside Sources: Price controls have no place in any future COVID-19 funding bill.
Op-EdsInsurers Are NOT Banks
Inside Sources: Insurers are not ATMs for another industry.
Op-EdsTrump doesn't need the Defense Production Act When Manufacturers are Already Stepping Up
Washington Examiner: If Trump did use this power, it could lead to unprecedented restrictions on private companies.
Op-EdsAfter Gottlieb, FDA Must Stop Dragging Feet on Less Risky Alternatives to Cigarettes
Fox Business: For the past 10 years, the FDA has failed to act promptly to consider and approve harm-reduction products.
Op-EdsHollow Promises On Feds’ Drug Discount Program
Daily Caller: Hospitals have been using the 340B program to enhance their own bottom line.
Op-EdsThe World Health Organization's Misguided Effort to Stop Americans from Vaping
The Hill: Next month, U.S. officials will have the opportunity to defend Americans’ freedom to vape.
Op-EdsCompulsory Pharmaceutical Licensing is Little More Than Government Theft
The Hill: Any reasonable person knows that nothing is free: someone must always pay.
